The awarded abstract presented real-world evidence of Stockholm3 performance outside Scandinavia, where most of the clinical data for Stockholm3 historically originates from, involving over 1,000 men across five centers in Germany, Switzerland, and Türkiye. The study compared Stockholm3 to PSA-based screening for detection of clinically significant prostate cancer (csPC), showing improved specificity and sensitivity across diverse European clinical practices.

Key findings include:

• In men with PSA between 1.5–3 ng/ml, Stockholm3 identified csPC in 32% of those biopsied—cancers that would likely have been missed by PSA alone
• 27% reduction in unnecessary positive tests when using Stockholm3 ≥11 versus PSA ≥3 ng/ml
• 3% increase in detection of csPC (ISUP grade ≥2 cancers)
• Fewer low-grade (ISUP 1) cancers and benign biopsies, enhancing diagnostic precision

“This study shows that Stockholm3 not only improves prostate cancer diagnostics within Scandinavian populations but also performs robustly across other European healthcare settings,” says Professor Derya Tilki, Principal Investigator of the study and MD at the Martini-Klinik Prostate Cancer Center at the University Hospital Hamburg-Eppendorf.

These findings reinforce the value of Stockholm3 in guiding MRI and biopsy decisions more effectively and optimizing care pathways for men at risk of prostate cancer.

The study adds to a growing body of international evidence supporting Stockholm3’s role in transforming early detection of aggressive prostate cancer, reducing overdiagnosis, and addressing global challenges in prostate cancer diagnostics.